Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)

The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused.

Original languageEnglish
Pages (from-to)749-750
Number of pages2
JournalJournal of the Formosan Medical Association
Volume117
Issue number8
DOIs
Publication statusPublished - 2018 Aug

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)'. Together they form a unique fingerprint.

Cite this